Ollin Biosciences Announces Oversubscribed $330 Million Series B Financing to Advance Global Phase 3 Development of OLN324 in DME and Wet AMD; Studies Commencing in Second Half of 2026

by Business Wire • 2026/06/24 • 0 Comments

AUSTIN, Texas--(BUSINESS WIRE)--Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases, today announced an oversubscribed $330 million Series B financing. The financing round was co-led by new investor TCGX and founding investor ARCH Venture Partners, with participation from a syndicate of leading healthcare-focused crossover investors, sovereign wealth funds and other institutional investors new to Ollin, including a16z Bio

← Tears: A Well of Diagnostic Info, No Crying Required

LambdaVision and Vast Sign Agreement to Advance Space-Based Manufacturing of Protein-Based Artificial Retina and Microgravity Bioprocesses →

Post navigation